Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Hatchette

Neurological Surgery Salem, OR Medical Doctor

NPI 1568662435 CMS profile 1285297

875 Oak St Se, Suite 5060, Salem, OR 97301

Open in the dashboard

General payments

$4,124

182 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Hatchette of Salem, OR is reported in the CMS Open Payments database as having received $4,124 across 182 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $126 4
2024 General $188 5
2023 General $282 10
2022 General $331 17
2021 General $820 39
2020 General $1,036 48
2019 General $1,341 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Hatchette
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Charles Hatchette were reported at $126. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Charles Hatchette Neurological Surgery median Middle half National median
2019 $1,341 $582 $138–$3,006 $163
2020 $1,036 $294 $76–$2,174 $114
2021 $820 $387 $105–$2,432 $132
2022 $331 $542 $139–$2,989 $149
2023 $282 $534 $145–$2,697 $160
2024 $188 $574 $155–$3,046 $164
2025 $126 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $2,378 107 payments
  2. Medtronic, Inc. $1,369 61 payments
  3. Abbott Laboratories $167 6 payments
  4. DePuy Synthes Sales Inc. $94 2 payments
  5. Globus Medical, Inc. $52 2 payments
  6. Integra LifeSciences Corporation $32 2 payments
  7. Bioventus LLC $16 1 payment
  8. Steelhead Surgical Inc $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,124 182 payments
Products named General payments · program years 2019–2025
  1. CD HORIZON Tl $879 40 payments
  2. CD HORIZON Tl $323 16 payments
  3. CD HORIZON SPINAL SYSTEM $273 13 payments
  4. INFINITY OCT System $227 10 payments
  5. PIVOX Oblique Lateral Spinal System Tl $198 9 payments
  6. O-ARM-Spine $156 7 payments
  7. SOVEREIGN $144 7 payments
  8. ELEVATE $140 7 payments
  9. PIVOX Oblique Lateral Spinal System Tl $109 6 payments
  10. CLYDESDALE $99 4 payments
  11. Other $1,784 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

26

Median for Neurosurgery: 83

Drug cost

$228

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 13 $120
Methocarbamol Generic 13 $107

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$122,390

Medicare's payments for the services billed

Medicare patients

177

Average age 73

Services billed

515

105 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 30%
Diabetes 29%
Ischemic heart disease 25%
Chronic kidney disease 23%
COPD 18%
Osteoporosis 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record